About GERM
GERM is designed to give direct exposure to the biotech companies directly engaged in the testing and treatments of infectious diseases. Focused on advancements with targeted exposure to the forefront of R&D, vaccines, therapies and testing technologies.
- From Jan. 2011 to Jan. 2018 there were 36 epidemic events in the U.S. alone.1
- New reports indicate the value of the global* human vaccines market is expected to grow to $72.5 billion by 2024, representing a CAGR of 11.2% from 2016 to 2024.2
- There are 20 combined pandemics and epidemics affecting the world today.3
-
Variations of Coronavirus have been medically documented in approx. 9 instances since 1965.4
About the Fund
The ETFMG Treatments, Testing and Advancements ETF (GERM) holds U.S.-listed companies engaged in and at the forefront of R&D, vaccines, therapies and testing technologies.
The Fund’s investment objective seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the Prime Treatments, Testing and Advancements Index.
About the Index
The Prime Treatments, Testing and Advancements Index (the “Index”) is an Index of Prime Indexes, a division of Level ETF Ventures LLC. The Index has been created to provide investors with a reference measure that enables them to track both event-driven news and long-term trends of companies engaged in developing treatments and vaccines, or diagnostic technology, in the fight against infectious diseases.
The Index is designed to include the securities of companies engaged in performing research, development and commercialization of treatments, vaccines or biological testing for infectious diseases. These companies are known collectively as “Treatments, Testing and Advancement Companies.”
1. World Health Organization, “Managing Epidemics”, page 22: https://www.who.int/emergencies/diseases/managing-epidemics-interactive.pdf?ua=1
2. Vaccines and Vaccination conference series, Transparency Market Research, June 2020, Market analysis: https://europe.vaccineconferences.com
3. World Health Organization: https://www.who.int/emergencies/diseases/en/
4. “The Scientist”: A Brief History of Human Coronavirus 6/2/2020: https://www.the-scientist.com/news-opinion/a-brief-history-of-human-coronaviruses-67600
5. World Economic Forum white paper, “Outbreak Readiness and Business Impact Protecting Lives and Livelihoods across the Global Economy”, in collaboration with Harvard Global Health Institute, Jan. 2019 http://www3.weforum.org/docs/WEF%20HGHI_Outbreak_Readiness_Business_Impact.pdf
Prime Indexes
Prime Indexes creates financial indexes that solve problems for both professional and self-directed investors. Prime Indexes are used as the basis for innovative new investment solutions for investors and use intuitive design principles so that new investment products can ultimately provide low-cost, efficient, and convenient access.
For more information, visit primeindexes.com
Related Funds
Fund Summary
Fund Documents
Research
Fund Prices
Last Updated 7/3/2020
Fund Name
ETFMG Treatments Testing and Advancements ETF
Symbol
GERM
NAV
27.93
Market Price Changes
0.40
Market Price Close
28.10
Nav Price Change
0.26
Premium/Discount(%)
0.61
Month End Performance
Last Updated 06/30/2020 |
NAV% | Market Value% |
|---|---|---|
| Cumulative | ||
| 1 Month | - | - |
| 3 Months | - | - |
| 6 Months | - | - |
| YTD | - | - |
| Since Inception Cumulative | 13.74 | 14.12 |
| Annual | ||
| 1 Year | - | - |
| 3 Year | - | - |
| 5 Year | - | - |
| Since Inception Annualized | - | - |
Quarter End Performance
Last Updated 06/30/2020 |
NAV% | Market Value% |
|---|---|---|
| Cumulative | ||
| 1 Month | - | - |
| 3 Months | - | - |
| 6 Months | - | - |
| YTD | - | - |
| Since Inception Cumulative | 13.74 | 14.12 |
| Annual | ||
| 1 Year | - | - |
| 3 Year | - | - |
| 5 Year | - | - |
| Since Inception Annualized | - | - |
Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance of the Funds may be lower or higher than the performance quoted. All performance is historical and includes reinvestment of dividends and capital gains. Performance data current to the most recent month end may be obtained by calling 1-844-ETF-MGRS (1-844-383-6477).
Top 10 Holdings
Fund holdings and sector allocations are subject to change at any time and should not be considered recommendations to buy or sell any security.
News Alert
ETFMG Adds Biotech to their Thematic ETF Lineup with GERM
